Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading Down 7.2% – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) dropped 7.2% during mid-day trading on Monday . The company traded as low as $44.1979 and last traded at $44.1979. Approximately 275 shares were traded during trading, a decline of 90% from the average daily volume of 2,766 shares. The stock had previously closed at $47.64.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Berenberg Bank cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 17th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S currently has an average rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average price is $47.50 and its 200 day moving average price is $47.10. The company has a market capitalization of $3.16 billion, a P/E ratio of 7.33 and a beta of 0.89.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.